Aims After non-vitamin K antagonist (VKA) oral anticoagulation agents (NOAC) have been
approved for thrombo-embolic prophylaxis in non-valvular atrial fibrillation (NVAF) …

There are few head-to-head trials directly comparing non-vitamin K antagonist oral
anticoagulants (NOACs) against one other. A network meta-analysis (NMA) was performed …

Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial …

Background: The J-RHYTHM Registry 2 was a multicenter, prospective observational study
that extended the follow-up period of the J-RHYTHM Registry in order to investigate long …

Background: Major atrial fibrillation (AF) guidelines recommend non-vitamin K antagonist
oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 …

Non-vitamin K antagonist oral anticoagulants (NOACs) are alternatives to vitamin K
antagonists to prevent stroke in patients with non-valvular atrial fibrillation (AF) and have …

What is known and objective Limited data are available for the comparison between different
non‐vitamin K antagonist oral anticoagulants (NOACs) on clinical outcomes. We aimed to …

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended in
preference to warfarin in most patients with atrial fibrillation when oral anticoagulation is …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background Non‐vitamin K antagonist oral anticoagulants (NOAC s) are broadly preferable
to vitamin K antagonists (VKA s) for stroke prevention in non‐valvular atrial fibrillation (AF) …